<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Nemaline Myopathy - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "â†³ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Nemaline Myopathy</span>
        </nav>

        <header class="page-header">
            <h1>Nemaline Myopathy</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018958" target="_blank">
                        MONDO:0018958
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Congenital Structural Myopathy</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Thin Filament Myopathy</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Nemaline myopathy (also called nemaline rod myopathy) is a group of congenital myopathies characterized by the presence of rod-shaped structures (nemaline bodies or rods) in skeletal muscle fibers on biopsy. It is the most common non-dystrophic congenital myopathy, affecting approximately 1 in 50,000 live births. Clinical features range from severe neonatal forms with respiratory failure to mild childhood-onset or adult-onset forms with proximal weakness. The disease is genetically heterogeneous, with mutations in at least 13 genes encoding components of the thin filament or associated proteins, most commonly NEB and ACTA1.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">ðŸ‘ª</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal Recessive
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000007" target="_blank">
                            HP:0000007
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Most cases of nemaline myopathy, particularly those due to NEB mutations (the most common cause), follow autosomal recessive inheritance.
</div>
                
                
    
    
    <div class="item-meta">
        
        <span class="tag tag-classification">
            Autosomal recessive inheritance
        </span>
        
        
        
        
        
    </div>
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36661122" target="_blank">PMID:36661122</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"NM is a genetic disorder and mutations in 12 genes are known to contribute to autosomal dominant or recessive forms of the disease. Recessive mutations in nebulin (NEB) are the most common cause of NM affecting about 50% of patients."</div>
                
                
                <div class="evidence-explanation">Confirms that recessive NEB mutations are the most common cause of nemaline myopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal Dominant
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000006" target="_blank">
                            HP:0000006
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Some forms, notably those caused by ACTA1 mutations, can follow autosomal dominant inheritance, though many ACTA1 cases are de novo.
</div>
                
                
    
    
    <div class="item-meta">
        
        <span class="tag tag-classification">
            Autosomal dominant inheritance
        </span>
        
        
        
        
        
    </div>
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38376469" target="_blank">PMID:38376469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Variants in ACTA1 (NEM3) comprise 15-25% of all nemaline myopathy cases."</div>
                
                
                <div class="evidence-explanation">Supports ACTA1 as a significant genetic cause; ACTA1 mutations can be autosomal dominant.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31228046" target="_blank">PMID:31228046</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nemaline myopathies are a heterogenous group of congenital myopathies caused by de novo, dominantly or recessively inherited mutations in at least twelve genes."</div>
                
                
                <div class="evidence-explanation">Authoritative review confirming de novo, dominant, and recessive inheritance patterns across NM genes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">â—†</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">5</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Severe Congenital Nemaline Myopathy
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The most severe form, presenting at birth with profound hypotonia, minimal spontaneous movement, severe respiratory insufficiency, and feeding difficulties. Often fatal in infancy. ACTA1 accounts for more than half of severe NM cases, with intranuclear rods, cytoplasmic bodies, and enlarged perinuclear space as characteristic ultrastructural hallmarks.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38500810" target="_blank">PMID:38500810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding."</div>
                
                
                <div class="evidence-explanation">Case report of severe congenital nemaline myopathy with hallmark features of the subtype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35810298" target="_blank">PMID:35810298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The patients manifested antenatal or neonatal muscle weakness requiring permanent respiratory assistance, and most deceased within the first months of life."</div>
                
                
                <div class="evidence-explanation">Cohort of 10 severe ACTA1-NM families documenting the fatal neonatal course.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35810298" target="_blank">PMID:35810298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ACTA1 accounts for more than half of the severe NM cases."</div>
                
                
                <div class="evidence-explanation">Establishes ACTA1 as the predominant cause of severe congenital NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Typical Congenital Nemaline Myopathy
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">The most common form, presenting in infancy or early childhood with hypotonia, proximal weakness, facial weakness, and feeding difficulties. Most patients achieve ambulation but may require respiratory support.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36960434" target="_blank">PMID:36960434</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We review varying presentations in children ranging in severity despite being caused by the same mutation, in addition to current and future clinical considerations relevant to the care of patients with NM."</div>
                
                
                <div class="evidence-explanation">Systematic review of pediatric NM describes the spectrum of presentations including the typical congenital form.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Childhood-Onset Nemaline Myopathy
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Presents between ages 2 and 15 with slowly progressive proximal weakness. Generally milder than the congenital forms.
</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Adult-Onset Nemaline Myopathy
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Late-onset form that can be sporadic and may be associated with HIV infection, monoclonal gammopathy, or other immunologic disorders. Presents with progressive proximal weakness in adulthood. May mimic inflammatory myopathy clinically and can present with isolated respiratory failure. Unlike inherited NM, sporadic late-onset NM (SLONM) is amenable to immunosuppressive therapy.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36703211" target="_blank">PMID:36703211</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy."</div>
                
                
                <div class="evidence-explanation">Describes sporadic late-onset nemaline myopathy as a distinct entity from inherited forms, amenable to therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9372751" target="_blank">PMID:9372751</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An adult-onset variant is characterized by large numbers of rod-containing myofibers, numerous rods per affected myofiber, and the absence of specific structural abnormalities typical of other muscle diseases."</div>
                
                
                <div class="evidence-explanation">Defines the adult-onset variant criteria and notes association with inflammatory and immunologic components.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19208402" target="_blank">PMID:19208402</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This case study reports a 60-year-old woman who presented with isolated type 2 respiratory failure secondary to bilateral hemidiaphragm weakness."</div>
                
                
                <div class="evidence-explanation">Documents that adult-onset NM can present with isolated respiratory failure as the sole manifestation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        NEM6 (KBTBD13-Related)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by KBTBD13 variants, characterized by a distinctive slowness of movements and delayed muscle relaxation, with a relatively mild overall phenotype but significant impact on daily activities through falls and fatigue.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39651462" target="_blank">PMID:39651462</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Key patient-reported symptoms since childhood were muscle weakness (n = 23; 96%), slowness of movements (n = 23; 96%), and difficulties with running (n = 20; 83%)."</div>
                
                
                <div class="evidence-explanation">Cross-sectional study of 24 NEM6 patients documenting the characteristic slowness of movements phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">âš™</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Thin Filament Dysfunction</div>
                
                <div class="item-desc">Mutations in genes encoding thin filament components (nebulin, skeletal alpha-actin, tropomyosins, troponins, cofilin-2, leiomodin-3) disrupt the normal structure and function of the sarcomeric thin filament. This leads to impaired actin-myosin cross-bridge cycling and reduced muscle force generation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Skeletal Muscle Fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Type I Muscle Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002211" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Skeletal Muscle Contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0003009" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Actin Filament Organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007015" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Skeletal Muscle Thin Filament Assembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030240" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nebulin, a critical protein of the skeletal muscle thin filament, plays important roles in physiological processes such as regulating thin filament length (TFL), cross-bridge cycling, and myofibril alignment."</div>
                
                
                <div class="evidence-explanation">Establishes the role of nebulin in thin filament function and the consequence of its disruption.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38376469" target="_blank">PMID:38376469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3"</div>
                
                
                <div class="evidence-explanation">Confirms ACTA1-related NM is an actin-based thin filament disease with impaired muscle function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Nemaline Rod Formation</div>
                
                <div class="item-desc">Nemaline rods are electron-dense inclusions composed of alpha-actinin, actin, tropomyosin, cofilin-2, telethonin, nebulin, and other Z-disc proteins. They are derived from Z lines and have a similar lattice structure and protein content. In inherited NM, rods are typically found in subsarcolemmal or central aggregates. Rod shape in KLHL40 and LMOD3 cases is distinctive. The number and distribution of rods does not correlate with severity or prognosis. In severe ACTA1 cases, intranuclear rods and cytoplasmic bodies are characteristic.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Sarcomere Organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0045214" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        â†• DYSREGULATED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36703211" target="_blank">PMID:36703211</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples."</div>
                
                
                <div class="evidence-explanation">Documents the distinct distribution pattern of nemaline rods in inherited vs acquired forms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38500810" target="_blank">PMID:38500810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Muscle biopsy analysis is crucial for the identification of pathognomonic morphological features, such as core areas, nemaline bodies or rods, nuclear centralizations and congenital type 1 fibers disproportion."</div>
                
                
                <div class="evidence-explanation">Confirms nemaline rods as a pathognomonic feature identified on muscle biopsy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31228046" target="_blank">PMID:31228046</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"These rods or nemaline bodies are derived from Z lines (also known as Z discs or Z disks) and have a similar lattice structure and protein content. Their shape in patients with mutations in KLHL40 and LMOD3 is distinctive and can be useful for diagnosis. The number and distribution of nemaline..."</div>
                
                
                <div class="evidence-explanation">Authoritative review establishing rod origin from Z-discs, gene-specific rod morphology, and lack of correlation between rod burden and clinical severity.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Thin Filament Length Dysregulation</div>
                
                <div class="item-desc">Nebulin acts as a molecular ruler specifying thin filament length. Loss of nebulin leads to shorter thin filaments, reducing the overlap zone with thick filaments and impairing force generation. Pathogenic NEB duplications can also produce longer-than-normal thin filaments, demonstrating that uniformity in thin filament length is critical and both shortened and elongated filaments are deleterious.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Sarcomere Organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0045214" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        â†• DYSREGULATED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We observed a positive relation between the reduction in nebulin and a reduction in TFL, or reduction in tension (both maximal and submaximal tension). Interestingly, our study revealed a pathogenic duplication variant in nebulin that resulted in a four-copy gain in the triplicate region of NEB..."</div>
                
                
                <div class="evidence-explanation">Demonstrates that both shortened and elongated thin filaments from NEB variants impair force generation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"we propose that the pathomechanism of NEM2 involves not only shortened but also elongated thin filaments, along with the disruption of actin-binding sites resulting from pathogenic splicing variants."</div>
                
                
                <div class="evidence-explanation">Proposes that thin filament length dysregulation in both directions is a key disease mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Ubiquitin-Proteasome Pathway Dysregulation (KLHL40)</div>
                
                <div class="item-desc">KLHL40 functions as a CUL3 E3 ubiquitin ligase substrate-specific adapter. Loss of KLHL40 disrupts ubiquitin-mediated degradation of SAR1A, leading to defective ER-to-Golgi vesicle trafficking, impaired extracellular matrix protein secretion, and downstream structural and functional abnormalities in skeletal muscle.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Protein Ubiquitination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016567" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        â†• DYSREGULATED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        ER to Golgi Vesicle-Mediated Transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006888" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        âš  ABNORMAL
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37432316" target="_blank">PMID:37432316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our studies identified a role for KLHL40 as a regulator of ER-Golgi anterograde trafficking through ubiquitin-mediated protein degradation of secretion-associated Ras-related GTPase1a (Sar1a). In KLHL40-deficient muscle, defects in ER exit site vesicle formation and downstream transport of..."</div>
                
                
                <div class="evidence-explanation">Establishes that KLHL40 deficiency causes NM through disrupted ubiquitin-regulated vesicle trafficking.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Nuclear Envelope Disruption (ACTA1)</div>
                
                <div class="item-desc">In severe ACTA1-NM, skeletal muscle alpha-actin contributes to nuclear shape maintenance. Mutant ACTA1 causes enlargement of the perinuclear space and abnormal localization of lamin A/C, Nesprin-1, and Nesprin-2, which form the nuclear lamina and LINC complex ensuring nuclear envelope integrity. This identifies a novel pathomechanistic axis beyond sarcomeric dysfunction.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35810298" target="_blank">PMID:35810298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We also detected structural anomalies of the perinuclear space, emphasizing a physiological contribution of skeletal muscle Î±-actin to nuclear shape."</div>
                
                
                <div class="evidence-explanation">Identifies perinuclear space enlargement as a novel ultrastructural hallmark of severe ACTA1-NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35810298" target="_blank">PMID:35810298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In-depth investigations of the nuclei confirmed an abnormal localization of lamin A/C, Nesprin-1, and Nesprin-2, forming the main constituents of the nuclear lamina and the LINC complex and ensuring nuclear envelope integrity."</div>
                
                
                <div class="evidence-explanation">Demonstrates disruption of nuclear envelope components in ACTA1-NM, linking actin mutations to nuclear biology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NRAP-Mediated Sarcomere Disorganization</div>
                
                <div class="item-desc">In nebulin deficiency, upregulation of the nebulin-related anchoring protein NRAP contributes to sarcomere structural defects and protein aggregate formation. NRAP acts as a disease modifier, and its reduction can rescue sarcomeric disorganization and eliminate nemaline bodies.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36661122" target="_blank">PMID:36661122</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our studies have identified Nrap upregulation in nebulin deficiency that contributes to structural and functional deficits in NM. We show that genetic ablation of nrap in nebulin deficiency restored sarcomeric disorganization, reduced protein aggregates and improved skeletal muscle function in zebrafish."</div>
                
                
                <div class="evidence-explanation">Identifies NRAP as a disease modifier in NEB-related NM with therapeutic targeting potential.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">â—</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">9</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Head and Neck<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Musculoskeletal<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Feeding Difficulties
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0008872" target="_blank">
                                Feeding difficulties in infancy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0008872)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38500810" target="_blank">PMID:38500810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding."</div>
                
                
                <div class="evidence-explanation">Documents feeding difficulties requiring gastrostomy in a neonate with NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"32% of patients with NM-NEB used a G tube"</div>
                
                
                <div class="evidence-explanation">Quantifies the frequency of gastrostomy tube use in NEB-NM patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Facial Weakness
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000276" target="_blank">
                                Long face
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000276)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Described for the first time, half of the patients presented tongue atrophy in a triple furrow pattern, and the presence of the atrophy was associated with dysphagia."</div>
                
                
                <div class="evidence-explanation">Identifies a novel facial/bulbar finding in NEB-NM patients associated with dysphagia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypotonia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38500810" target="_blank">PMID:38500810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding."</div>
                
                
                <div class="evidence-explanation">Case report demonstrating severe hypotonia as a presenting feature in neonatal NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36661122" target="_blank">PMID:36661122</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nemaline myopathy (NM) is a rare neuromuscular disorder associated with congenital or childhood-onset of skeletal muscle weakness and hypotonia, which results in limited motor function."</div>
                
                
                <div class="evidence-explanation">Establishes hypotonia as a defining feature of nemaline myopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17272906" target="_blank">PMID:17272906</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"All of them presented in childhood (first five years of life) with generalized hypotonia, feeding problems, repeated respiratory infections and muscle weakness."</div>
                
                
                <div class="evidence-explanation">Indian cohort confirming generalized hypotonia as a universal presenting feature in childhood-onset NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Respiratory Insufficiency
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002747" target="_blank">
                                Respiratory insufficiency due to muscle weakness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002747)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"32% of patients with NM-NEB used a G tube, 35% were not able to walk without support, and 55% needed VS."</div>
                
                
                <div class="evidence-explanation">Documents that 55% of NEB-NM patients required ventilatory support.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Grouping patients by age suggested disease stability in motor and swallow function, but a progression in respiratory dysfunction and skeletal deformities."</div>
                
                
                <div class="evidence-explanation">Shows progressive respiratory involvement in NEB-NM patients over time.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19208402" target="_blank">PMID:19208402</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This case study reports a 60-year-old woman who presented with isolated type 2 respiratory failure secondary to bilateral hemidiaphragm weakness."</div>
                
                
                <div class="evidence-explanation">Documents that NM can present with isolated respiratory failure from diaphragm weakness, highlighting the importance of considering neuromuscular causes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Scoliosis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002650" target="_blank">
                                Scoliosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002650)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Scoliosis and dysphagia were more common among patients who used VS."</div>
                
                
                <div class="evidence-explanation">Documents association of scoliosis with disease severity in NEB-NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Comparing the patients grouped by age, we found that, proportionally, older patients had more scoliosis and respiratory dysfunction than younger groups, suggesting the progression of the disease in these domains."</div>
                
                
                <div class="evidence-explanation">Demonstrates progressive scoliosis with increasing age in NEB-NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Generalized Muscle Weakness
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003324" target="_blank">
                                Generalized muscle weakness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003324)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenic variants in the nebulin gene (NEB) cause NEB-based nemaline myopathy (NEM2), a genetically heterogeneous disorder characterized by hypotonia and muscle weakness, currently lacking curative therapies."</div>
                
                
                <div class="evidence-explanation">Confirms muscle weakness as a cardinal feature of NEB-based nemaline myopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The clinical spectrum of NM caused by NEB pathogenic variants (NM-NEB) is very broad, ranging from mild to severe presentations manifesting with generalized weakness, as well as respiratory and bulbar involvement."</div>
                
                
                <div class="evidence-explanation">Documents generalized weakness across the spectrum of NEB-NM in a 33-patient cohort.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nemaline Bodies
                        
                        <span class="phenotype-freq">OBLIGATE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003798" target="_blank">
                                Nemaline bodies
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003798)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36703211" target="_blank">PMID:36703211</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers."</div>
                
                
                <div class="evidence-explanation">Confirms nemaline rod accumulation as the defining feature across NM subtypes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9372751" target="_blank">PMID:9372751</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A modified trichrome stain of the right biceps muscle revealed granular, basophilic, centrally located rods in the atrophic myofibers. Ultrastructurally, these myofibers contained osmiophilic rectangular structures with a latticelike appearance typical of nemaline myopathy."</div>
                
                
                <div class="evidence-explanation">Classic description of nemaline rod morphology on trichrome stain and electron microscopy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39691005" target="_blank">PMID:39691005</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Modified Gomori trichrome staining revealed granular deposits in the myofibers. Ultrastructure examination showed numerous nemaline rods in the myofibers"</div>
                
                
                <div class="evidence-explanation">Recent case confirming characteristic trichrome and ultrastructural appearance of nemaline rods.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Slowness of Movements
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39651462" target="_blank">PMID:39651462</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Key patient-reported symptoms since childhood were muscle weakness (n = 23; 96%), slowness of movements (n = 23; 96%), and difficulties with running (n = 20; 83%)."</div>
                
                
                <div class="evidence-explanation">Documents slowness of movements as a near-universal symptom in NEM6 patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39651462" target="_blank">PMID:39651462</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This might be related to delayed muscle relaxation."</div>
                
                
                <div class="evidence-explanation">Links the slowness of movements phenotype to the delayed muscle relaxation kinetics measured in NEM6 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        High Palate
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000218" target="_blank">
                                High palate
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000218)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">ðŸ§¬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NEB Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36661122" target="_blank">PMID:36661122</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recessive mutations in nebulin (NEB) are the most common cause of NM affecting about 50% of patients."</div>
                
                
                <div class="evidence-explanation">Establishes NEB as the most common causative gene in NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenic variants in the nebulin gene (NEB) cause NEB-based nemaline myopathy (NEM2), a genetically heterogeneous disorder characterized by hypotonia and muscle weakness"</div>
                
                
                <div class="evidence-explanation">Confirms NEB variants as causative for NEM2.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31228046" target="_blank">PMID:31228046</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The genes encoding skeletal Î±-actin (ACTA1) and nebulin (NEB) are the commonest genetic cause."</div>
                
                
                <div class="evidence-explanation">Authoritative 2019 review confirming NEB and ACTA1 as the two most common causative genes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ACTA1 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38376469" target="_blank">PMID:38376469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Variants in ACTA1 (NEM3) comprise 15-25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death."</div>
                
                
                <div class="evidence-explanation">Establishes ACTA1 as the second most common cause of NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38500810" target="_blank">PMID:38500810</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An expanded Next Generation Sequencing analysis targeting congenital myopathies genes revealed the presence of a novel heterozygous c.965 T &gt; A p. (Leu322Gln) variant in the ACTA1 gene, which encodes the skeletal muscle alpha-actin."</div>
                
                
                <div class="evidence-explanation">Case report of a novel ACTA1 variant causing NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35810298" target="_blank">PMID:35810298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"ACTA1 encodes Î±-actin, one of the principal components of the contractile units in skeletal muscle."</div>
                
                
                <div class="evidence-explanation">Describes ACTA1 function and confirms its role in severe NM with characteristic intranuclear rods and perinuclear space abnormalities.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KBTBD13 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39651462" target="_blank">PMID:39651462</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nemaline myopathy type 6 (NEM6) is the most prevalent type of nemaline myopathy in the Netherlands."</div>
                
                
                <div class="evidence-explanation">Establishes KBTBD13-NEM6 as a significant form of NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KLHL40 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37432316" target="_blank">PMID:37432316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in KLHL40, an E3 ubiquitin ligase cullin3 (CUL3) substrate-specific adapter protein, result in severe congenital nemaline myopathy"</div>
                
                
                <div class="evidence-explanation">Confirms KLHL40 mutations as causative for severe congenital NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TPM3 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TPM2 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNNT1 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CFL2 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    LMOD3 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KLHL41 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">ðŸ’Š</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Respiratory Support
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000506" target="_blank">
                            MAXO:0000506
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Nocturnal non-invasive ventilation (BiPAP) or continuous ventilatory support for respiratory muscle weakness. In NEB-NM, 55% of patients require ventilatory support with progressive need over time.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"32% of patients with NM-NEB used a G tube, 35% were not able to walk without support, and 55% needed VS."</div>
                
                
                <div class="evidence-explanation">Documents that the majority of NEB-NM patients require ventilatory support.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Physical Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Ongoing physical therapy and rehabilitation to maintain mobility, prevent contractures, and optimize functional capacity.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nutritional Support
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001346" target="_blank">
                            MAXO:0001346
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Gastrostomy tube feeding for patients with severe bulbar weakness and failure to thrive. In NEB-NM, 32% of patients require gastrostomy.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36714460" target="_blank">PMID:36714460</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"32% of patients with NM-NEB used a G tube"</div>
                
                
                <div class="evidence-explanation">Quantifies the need for gastrostomy in NEB-NM patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Orthopedic Management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000477" target="_blank">
                            MAXO:0000477
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Management of scoliosis (bracing or surgical correction), foot deformities, and joint contractures.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for families to understand inheritance patterns, recurrence risk, and genetic testing options.
</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Fast Skeletal Muscle Troponin Activators (Investigational)
                    
                </div>
                
                
                <div class="item-desc">Tirasemtiv and related fast skeletal muscle troponin activators increase submaximal muscle tension in preclinical NM models by enhancing thin filament calcium sensitivity. Improved respiratory efficiency observed in NEM3 mouse models.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38376469" target="_blank">PMID:38376469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo."</div>
                
                
                <div class="evidence-explanation">Demonstrates tirasemtiv efficacy in a mouse model of ACTA1-related NM.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38376469" target="_blank">PMID:38376469</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration."</div>
                
                
                <div class="evidence-explanation">Shows improved respiratory efficiency with troponin activator treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Myosin Activators (Investigational)
                    
                </div>
                
                
                <div class="item-desc">Omecamtiv mecarbil, a small-molecule cardiac myosin activator, substantially increased submaximal tension in type 1 muscle fibers from NEB-NM patients, with the largest effects in those with the lowest nebulin levels.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38634969" target="_blank">PMID:38634969</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"OM treatment substantially increased submaximal tension across all NEM2 patients ranging from 87 to 318%, with the largest effects in patients with the lowest level of nebulin."</div>
                
                
                <div class="evidence-explanation">Ex vivo human muscle fiber data showing omecamtiv mecarbil increases force production in NEB-NM.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Nemaline Myopathy
creation_date: &#39;2026-02-19T00:00:00Z&#39;
updated_date: &#39;2026-02-19T00:00:00Z&#39;
category: Mendelian
description: &gt;
  Nemaline myopathy (also called nemaline rod myopathy) is a group of congenital
  myopathies characterized by the presence of rod-shaped structures (nemaline bodies
  or rods) in skeletal muscle fibers on biopsy. It is the most common non-dystrophic
  congenital myopathy, affecting approximately 1 in 50,000 live births. Clinical
  features range from severe neonatal forms with respiratory failure to mild
  childhood-onset or adult-onset forms with proximal weakness. The disease is
  genetically heterogeneous, with mutations in at least 13 genes encoding components
  of the thin filament or associated proteins, most commonly NEB and ACTA1.
disease_term:
  preferred_term: nemaline myopathy
  term:
    id: MONDO:0018958
    label: nemaline myopathy
parents:
- Congenital Structural Myopathy
- Thin Filament Myopathy
inheritance:
- name: Autosomal Recessive
  description: &gt;
    Most cases of nemaline myopathy, particularly those due to NEB mutations
    (the most common cause), follow autosomal recessive inheritance.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:36661122
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;NM is a genetic disorder and mutations in 12 genes are known to contribute to autosomal dominant or recessive forms of the disease. Recessive mutations in nebulin (NEB) are the most common cause of NM affecting about 50% of patients.&#34;
    explanation: Confirms that recessive NEB mutations are the most common cause of nemaline myopathy.
- name: Autosomal Dominant
  description: &gt;
    Some forms, notably those caused by ACTA1 mutations, can follow autosomal
    dominant inheritance, though many ACTA1 cases are de novo.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:38376469
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Variants in ACTA1 (NEM3) comprise 15-25% of all nemaline myopathy cases.&#34;
    explanation: Supports ACTA1 as a significant genetic cause; ACTA1 mutations can be autosomal dominant.
  - reference: PMID:31228046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Nemaline myopathies are a heterogenous group of congenital myopathies caused by de novo, dominantly or recessively inherited mutations in at least twelve genes.&#34;
    explanation: Authoritative review confirming de novo, dominant, and recessive inheritance patterns across NM genes.
has_subtypes:
- name: Severe Congenital Nemaline Myopathy
  description: &gt;
    The most severe form, presenting at birth with profound hypotonia, minimal
    spontaneous movement, severe respiratory insufficiency, and feeding difficulties.
    Often fatal in infancy. ACTA1 accounts for more than half of severe NM cases,
    with intranuclear rods, cytoplasmic bodies, and enlarged perinuclear space as
    characteristic ultrastructural hallmarks.
  evidence:
  - reference: PMID:38500810
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding.&#34;
    explanation: Case report of severe congenital nemaline myopathy with hallmark features of the subtype.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The patients manifested antenatal or neonatal muscle weakness requiring permanent respiratory assistance, and most deceased within the first months of life.&#34;
    explanation: Cohort of 10 severe ACTA1-NM families documenting the fatal neonatal course.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;ACTA1 accounts for more than half of the severe NM cases.&#34;
    explanation: Establishes ACTA1 as the predominant cause of severe congenital NM.
- name: Typical Congenital Nemaline Myopathy
  description: &gt;
    The most common form, presenting in infancy or early childhood with hypotonia,
    proximal weakness, facial weakness, and feeding difficulties. Most patients
    achieve ambulation but may require respiratory support.
  evidence:
  - reference: PMID:36960434
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We review varying presentations in children ranging in severity despite being caused by the same mutation, in addition to current and future clinical considerations relevant to the care of patients with NM.&#34;
    explanation: Systematic review of pediatric NM describes the spectrum of presentations including the typical congenital form.
- name: Childhood-Onset Nemaline Myopathy
  description: &gt;
    Presents between ages 2 and 15 with slowly progressive proximal weakness.
    Generally milder than the congenital forms.
- name: Adult-Onset Nemaline Myopathy
  description: &gt;
    Late-onset form that can be sporadic and may be associated with HIV infection,
    monoclonal gammopathy, or other immunologic disorders. Presents with progressive
    proximal weakness in adulthood. May mimic inflammatory myopathy clinically and
    can present with isolated respiratory failure. Unlike inherited NM, sporadic
    late-onset NM (SLONM) is amenable to immunosuppressive therapy.
  evidence:
  - reference: PMID:36703211
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy.&#34;
    explanation: Describes sporadic late-onset nemaline myopathy as a distinct entity from inherited forms, amenable to therapy.
  - reference: PMID:9372751
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;An adult-onset variant is characterized by large numbers of rod-containing myofibers, numerous rods per affected myofiber, and the absence of specific structural abnormalities typical of other muscle diseases.&#34;
    explanation: Defines the adult-onset variant criteria and notes association with inflammatory and immunologic components.
  - reference: PMID:19208402
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This case study reports a 60-year-old woman who presented with isolated type 2 respiratory failure secondary to bilateral hemidiaphragm weakness.&#34;
    explanation: Documents that adult-onset NM can present with isolated respiratory failure as the sole manifestation.
  - reference: PMID:39691005
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Sporadic late-onset nemaline rod myopathy is a rare, acquired, sub-acute, adult-onset myopathy characterized by proximal muscle weakness and nemaline rods in the myofibers.&#34;
    explanation: Recent case confirming sporadic late-onset NM as a distinct acquired entity with monoclonal protein association.
  - reference: PMID:6481414
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;A woman, aged 75 years, presented with a 15-year history of progressive, generalized, painful muscle weakness and wasting.&#34;
    explanation: Early case report of adult-onset NM with mixed pathology (rods, minicores, cores) mimicking polymyositis.
- name: NEM6 (KBTBD13-Related)
  description: &gt;
    Caused by KBTBD13 variants, characterized by a distinctive slowness of movements
    and delayed muscle relaxation, with a relatively mild overall phenotype but
    significant impact on daily activities through falls and fatigue.
  evidence:
  - reference: PMID:39651462
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Key patient-reported symptoms since childhood were muscle weakness (n = 23; 96%), slowness of movements (n = 23; 96%), and difficulties with running (n = 20; 83%).&#34;
    explanation: Cross-sectional study of 24 NEM6 patients documenting the characteristic slowness of movements phenotype.
pathophysiology:
- name: Thin Filament Dysfunction
  description: &gt;
    Mutations in genes encoding thin filament components (nebulin, skeletal alpha-actin,
    tropomyosins, troponins, cofilin-2, leiomodin-3) disrupt the normal structure
    and function of the sarcomeric thin filament. This leads to impaired actin-myosin
    cross-bridge cycling and reduced muscle force generation.
  cell_types:
  - preferred_term: Skeletal Muscle Fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  - preferred_term: Type I Muscle Cell
    term:
      id: CL:0002211
      label: type I muscle cell
  biological_processes:
  - preferred_term: Skeletal Muscle Contraction
    term:
      id: GO:0003009
      label: skeletal muscle contraction
  - preferred_term: Actin Filament Organization
    term:
      id: GO:0007015
      label: actin filament organization
  - preferred_term: Skeletal Muscle Thin Filament Assembly
    term:
      id: GO:0030240
      label: skeletal muscle thin filament assembly
  evidence:
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Nebulin, a critical protein of the skeletal muscle thin filament, plays important roles in physiological processes such as regulating thin filament length (TFL), cross-bridge cycling, and myofibril alignment.&#34;
    explanation: Establishes the role of nebulin in thin filament function and the consequence of its disruption.
  - reference: PMID:38376469
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3&#34;
    explanation: Confirms ACTA1-related NM is an actin-based thin filament disease with impaired muscle function.
- name: Nemaline Rod Formation
  description: &gt;
    Nemaline rods are electron-dense inclusions composed of alpha-actinin, actin,
    tropomyosin, cofilin-2, telethonin, nebulin, and other Z-disc proteins. They
    are derived from Z lines and have a similar lattice structure and protein content.
    In inherited NM, rods are typically found in subsarcolemmal or central aggregates.
    Rod shape in KLHL40 and LMOD3 cases is distinctive. The number and distribution
    of rods does not correlate with severity or prognosis. In severe ACTA1 cases,
    intranuclear rods and cytoplasmic bodies are characteristic.
  biological_processes:
  - preferred_term: Sarcomere Organization
    modifier: DYSREGULATED
    term:
      id: GO:0045214
      label: sarcomere organization
  evidence:
  - reference: PMID:36703211
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples.&#34;
    explanation: Documents the distinct distribution pattern of nemaline rods in inherited vs acquired forms.
  - reference: PMID:38500810
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Muscle biopsy analysis is crucial for the identification of pathognomonic morphological features, such as core areas, nemaline bodies or rods, nuclear centralizations and congenital type 1 fibers disproportion.&#34;
    explanation: Confirms nemaline rods as a pathognomonic feature identified on muscle biopsy.
  - reference: PMID:31228046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;These rods or nemaline bodies are derived from Z lines (also known as Z discs or Z disks) and have a similar lattice structure and protein content. Their shape in patients with mutations in KLHL40 and LMOD3 is distinctive and can be useful for diagnosis. The number and distribution of nemaline bodies varies between fibres and different muscles but does not correlate with severity or prognosis.&#34;
    explanation: Authoritative review establishing rod origin from Z-discs, gene-specific rod morphology, and lack of correlation between rod burden and clinical severity.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Morphological analyses of the muscle biopsy specimens showed characteristic features of NM histopathology including cytoplasmic and intranuclear rods, cytoplasmic bodies, and major myofibrillar disorganization.&#34;
    explanation: Documents intranuclear rods and cytoplasmic bodies as characteristic features of severe ACTA1-NM.
  - reference: PMID:17272906
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;characteristic red-colored material was seen on modified Gomori trichrome staining which was immunopositive to alpha actinin. Ultrastructural examination confirmed this material to be nemaline rods.&#34;
    explanation: Confirms alpha-actinin as a major component of nemaline rods demonstrated by immunostaining.
- name: Thin Filament Length Dysregulation
  description: &gt;
    Nebulin acts as a molecular ruler specifying thin filament length. Loss of
    nebulin leads to shorter thin filaments, reducing the overlap zone with thick
    filaments and impairing force generation. Pathogenic NEB duplications can also
    produce longer-than-normal thin filaments, demonstrating that uniformity in
    thin filament length is critical and both shortened and elongated filaments
    are deleterious.
  biological_processes:
  - preferred_term: Sarcomere Organization
    modifier: DYSREGULATED
    term:
      id: GO:0045214
      label: sarcomere organization
  evidence:
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We observed a positive relation between the reduction in nebulin and a reduction in TFL, or reduction in tension (both maximal and submaximal tension). Interestingly, our study revealed a pathogenic duplication variant in nebulin that resulted in a four-copy gain in the triplicate region of NEB and a much larger nebulin protein and longer TFL.&#34;
    explanation: Demonstrates that both shortened and elongated thin filaments from NEB variants impair force generation.
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;we propose that the pathomechanism of NEM2 involves not only shortened but also elongated thin filaments, along with the disruption of actin-binding sites resulting from pathogenic splicing variants.&#34;
    explanation: Proposes that thin filament length dysregulation in both directions is a key disease mechanism.
- name: Ubiquitin-Proteasome Pathway Dysregulation (KLHL40)
  description: &gt;
    KLHL40 functions as a CUL3 E3 ubiquitin ligase substrate-specific adapter.
    Loss of KLHL40 disrupts ubiquitin-mediated degradation of SAR1A, leading to
    defective ER-to-Golgi vesicle trafficking, impaired extracellular matrix protein
    secretion, and downstream structural and functional abnormalities in skeletal
    muscle.
  biological_processes:
  - preferred_term: Protein Ubiquitination
    modifier: DYSREGULATED
    term:
      id: GO:0016567
      label: protein ubiquitination
  - preferred_term: ER to Golgi Vesicle-Mediated Transport
    modifier: ABNORMAL
    term:
      id: GO:0006888
      label: endoplasmic reticulum to Golgi vesicle-mediated transport
  evidence:
  - reference: PMID:37432316
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Our studies identified a role for KLHL40 as a regulator of ER-Golgi anterograde trafficking through ubiquitin-mediated protein degradation of secretion-associated Ras-related GTPase1a (Sar1a). In KLHL40-deficient muscle, defects in ER exit site vesicle formation and downstream transport of extracellular cargo proteins result in structural and functional abnormalities.&#34;
    explanation: Establishes that KLHL40 deficiency causes NM through disrupted ubiquitin-regulated vesicle trafficking.
- name: Nuclear Envelope Disruption (ACTA1)
  description: &gt;
    In severe ACTA1-NM, skeletal muscle alpha-actin contributes to nuclear
    shape maintenance. Mutant ACTA1 causes enlargement of the perinuclear space
    and abnormal localization of lamin A/C, Nesprin-1, and Nesprin-2, which
    form the nuclear lamina and LINC complex ensuring nuclear envelope integrity.
    This identifies a novel pathomechanistic axis beyond sarcomeric dysfunction.
  evidence:
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We also detected structural anomalies of the perinuclear space, emphasizing a physiological contribution of skeletal muscle Î±-actin to nuclear shape.&#34;
    explanation: Identifies perinuclear space enlargement as a novel ultrastructural hallmark of severe ACTA1-NM.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In-depth investigations of the nuclei confirmed an abnormal localization of lamin A/C, Nesprin-1, and Nesprin-2, forming the main constituents of the nuclear lamina and the LINC complex and ensuring nuclear envelope integrity.&#34;
    explanation: Demonstrates disruption of nuclear envelope components in ACTA1-NM, linking actin mutations to nuclear biology.
- name: NRAP-Mediated Sarcomere Disorganization
  description: &gt;
    In nebulin deficiency, upregulation of the nebulin-related anchoring protein
    NRAP contributes to sarcomere structural defects and protein aggregate formation.
    NRAP acts as a disease modifier, and its reduction can rescue sarcomeric
    disorganization and eliminate nemaline bodies.
  evidence:
  - reference: PMID:36661122
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Our studies have identified Nrap upregulation in nebulin deficiency that contributes to structural and functional deficits in NM. We show that genetic ablation of nrap in nebulin deficiency restored sarcomeric disorganization, reduced protein aggregates and improved skeletal muscle function in zebrafish.&#34;
    explanation: Identifies NRAP as a disease modifier in NEB-related NM with therapeutic targeting potential.
phenotypes:
- category: Musculoskeletal
  name: Generalized Muscle Weakness
  frequency: VERY_FREQUENT
  description: &gt;
    Proximal greater than distal muscle weakness, predominantly affecting limb-girdle
    and axial muscles. In NEB-NM, 35% are unable to walk without support.
  phenotype_term:
    preferred_term: Generalized muscle weakness
    term:
      id: HP:0003324
      label: Generalized muscle weakness
  evidence:
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Pathogenic variants in the nebulin gene (NEB) cause NEB-based nemaline myopathy (NEM2), a genetically heterogeneous disorder characterized by hypotonia and muscle weakness, currently lacking curative therapies.&#34;
    explanation: Confirms muscle weakness as a cardinal feature of NEB-based nemaline myopathy.
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The clinical spectrum of NM caused by NEB pathogenic variants (NM-NEB) is very broad, ranging from mild to severe presentations manifesting with generalized weakness, as well as respiratory and bulbar involvement.&#34;
    explanation: Documents generalized weakness across the spectrum of NEB-NM in a 33-patient cohort.
- category: Musculoskeletal
  name: Hypotonia
  frequency: VERY_FREQUENT
  description: &gt;
    Decreased muscle tone, often severe in congenital forms, presenting as floppy
    infant syndrome.
  phenotype_term:
    preferred_term: Muscular hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:38500810
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding.&#34;
    explanation: Case report demonstrating severe hypotonia as a presenting feature in neonatal NM.
  - reference: PMID:36661122
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Nemaline myopathy (NM) is a rare neuromuscular disorder associated with congenital or childhood-onset of skeletal muscle weakness and hypotonia, which results in limited motor function.&#34;
    explanation: Establishes hypotonia as a defining feature of nemaline myopathy.
  - reference: PMID:17272906
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;All of them presented in childhood (first five years of life) with generalized hypotonia, feeding problems, repeated respiratory infections and muscle weakness.&#34;
    explanation: Indian cohort confirming generalized hypotonia as a universal presenting feature in childhood-onset NM.
- category: Musculoskeletal
  name: Facial Weakness
  frequency: FREQUENT
  description: &gt;
    Weakness of facial muscles producing an elongated face. In NEB-NM, tongue
    atrophy in a triple furrow pattern is a novel and frequent finding associated
    with dysphagia.
  phenotype_term:
    preferred_term: Long face
    term:
      id: HP:0000276
      label: Long face
  evidence:
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Described for the first time, half of the patients presented tongue atrophy in a triple furrow pattern, and the presence of the atrophy was associated with dysphagia.&#34;
    explanation: Identifies a novel facial/bulbar finding in NEB-NM patients associated with dysphagia.
- category: Respiratory
  name: Respiratory Insufficiency
  frequency: FREQUENT
  description: &gt;
    Weakness of respiratory muscles leads to hypoventilation. In NEB-NM, 55% of
    patients required ventilatory support, with progressive respiratory involvement
    over time.
  phenotype_term:
    preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;32% of patients with NM-NEB used a G tube, 35% were not able to walk without support, and 55% needed VS.&#34;
    explanation: Documents that 55% of NEB-NM patients required ventilatory support.
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Grouping patients by age suggested disease stability in motor and swallow function, but a progression in respiratory dysfunction and skeletal deformities.&#34;
    explanation: Shows progressive respiratory involvement in NEB-NM patients over time.
  - reference: PMID:19208402
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This case study reports a 60-year-old woman who presented with isolated type 2 respiratory failure secondary to bilateral hemidiaphragm weakness.&#34;
    explanation: Documents that NM can present with isolated respiratory failure from diaphragm weakness, highlighting the importance of considering neuromuscular causes.
- category: Musculoskeletal
  name: Feeding Difficulties
  frequency: FREQUENT
  description: &gt;
    Difficulty with sucking and swallowing in infancy due to bulbar muscle weakness.
    In NEB-NM, 32% of patients require gastrostomy tube feeding, and dysphagia
    is associated with ventilatory support use.
  phenotype_term:
    preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  evidence:
  - reference: PMID:38500810
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Here, we describe an Italian newborn presenting with severe hypotonia, respiratory insufficiency, inability to suck and swallow, requiring mechanical ventilation and gastrostomy feeding.&#34;
    explanation: Documents feeding difficulties requiring gastrostomy in a neonate with NM.
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;32% of patients with NM-NEB used a G tube&#34;
    explanation: Quantifies the frequency of gastrostomy tube use in NEB-NM patients.
- category: Musculoskeletal
  name: Scoliosis
  frequency: FREQUENT
  description: &gt;
    Progressive scoliosis due to chronic axial muscle weakness. In NEB-NM,
    scoliosis is more common among patients using ventilatory support and
    in older age groups, suggesting disease progression.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Scoliosis and dysphagia were more common among patients who used VS.&#34;
    explanation: Documents association of scoliosis with disease severity in NEB-NM.
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Comparing the patients grouped by age, we found that, proportionally, older patients had more scoliosis and respiratory dysfunction than younger groups, suggesting the progression of the disease in these domains.&#34;
    explanation: Demonstrates progressive scoliosis with increasing age in NEB-NM.
- category: Musculoskeletal
  name: Nemaline Bodies
  frequency: OBLIGATE
  description: &gt;
    Rod-shaped inclusions composed of Z-disc and thin filament proteins visible
    on modified Gomori trichrome stain and electron microscopy. The defining
    histopathological feature of nemaline myopathy. Rods stain red on modified
    Gomori trichrome and show electron-dense lattice-like structures on EM.
  phenotype_term:
    preferred_term: Nemaline bodies
    term:
      id: HP:0003798
      label: Nemaline bodies
  evidence:
  - reference: PMID:36703211
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers.&#34;
    explanation: Confirms nemaline rod accumulation as the defining feature across NM subtypes.
  - reference: PMID:9372751
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;A modified trichrome stain of the right biceps muscle revealed granular, basophilic, centrally located rods in the atrophic myofibers. Ultrastructurally, these myofibers contained osmiophilic rectangular structures with a latticelike appearance typical of nemaline myopathy.&#34;
    explanation: Classic description of nemaline rod morphology on trichrome stain and electron microscopy.
  - reference: PMID:39691005
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Modified Gomori trichrome staining revealed granular deposits in the myofibers. Ultrastructure examination showed numerous nemaline rods in the myofibers&#34;
    explanation: Recent case confirming characteristic trichrome and ultrastructural appearance of nemaline rods.
- category: Musculoskeletal
  name: Slowness of Movements
  frequency: OCCASIONAL
  description: &gt;
    Distinctive slowness of movements and delayed muscle relaxation, particularly
    characteristic of KBTBD13-related NEM6 with median relaxation rate well below
    normal limits.
  evidence:
  - reference: PMID:39651462
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Key patient-reported symptoms since childhood were muscle weakness (n = 23; 96%), slowness of movements (n = 23; 96%), and difficulties with running (n = 20; 83%).&#34;
    explanation: Documents slowness of movements as a near-universal symptom in NEM6 patients.
  - reference: PMID:39651462
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This might be related to delayed muscle relaxation.&#34;
    explanation: Links the slowness of movements phenotype to the delayed muscle relaxation kinetics measured in NEM6 patients.
- category: Musculoskeletal
  name: High Palate
  frequency: FREQUENT
  description: &gt;
    High-arched palate associated with facial muscle weakness and elongated facies.
  phenotype_term:
    preferred_term: High palate
    term:
      id: HP:0000218
      label: High palate
epidemiology:
- name: Incidence
  description: Nemaline myopathy affects approximately 1 in 50,000 live births.
  notes: &gt;
    Estimated incidence varies by source from 1 in 50,000 to 2 per 100,000 live births.
    NM comprises approximately 0.5% of all muscle diseases and over 20% of congenital myopathies.
  evidence:
  - reference: PMID:36960434
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Nemaline myopathy is a skeletal muscle disease that affects 1 in 50 000 live births.&#34;
    explanation: Establishes the incidence of nemaline myopathy from a systematic review.
  - reference: PMID:17272906
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;NM comprises 0.53% of all muscle diseases and 22.6% of all congenital myopathies.&#34;
    explanation: Quantifies NM as a proportion of all muscle diseases and congenital myopathies from an Indian cohort.
genetic:
- name: NEB Mutations
  association: Causative
  notes: &gt;
    Mutations in NEB, encoding nebulin, are the most common cause of nemaline
    myopathy, accounting for approximately 50% of cases. Most are compound
    heterozygous mutations. Nebulin is a giant sarcomeric protein that spans
    the thin filament and regulates its length.
  evidence:
  - reference: PMID:36661122
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Recessive mutations in nebulin (NEB) are the most common cause of NM affecting about 50% of patients.&#34;
    explanation: Establishes NEB as the most common causative gene in NM.
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Pathogenic variants in the nebulin gene (NEB) cause NEB-based nemaline myopathy (NEM2), a genetically heterogeneous disorder characterized by hypotonia and muscle weakness&#34;
    explanation: Confirms NEB variants as causative for NEM2.
  - reference: PMID:31228046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The genes encoding skeletal Î±-actin (ACTA1) and nebulin (NEB) are the commonest genetic cause.&#34;
    explanation: Authoritative 2019 review confirming NEB and ACTA1 as the two most common causative genes.
- name: ACTA1 Mutations
  association: Causative
  notes: &gt;
    Mutations in ACTA1, encoding skeletal muscle alpha-actin, are the second
    most common cause, accounting for 15-25% of all NM cases but more than
    half of severe cases. Can be autosomal dominant (often de novo) or recessive.
    Severe ACTA1-NM features intranuclear rods and enlarged perinuclear space.
    Compensatory cardiac alpha-actin upregulation may modify disease severity.
  evidence:
  - reference: PMID:38376469
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Variants in ACTA1 (NEM3) comprise 15-25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death.&#34;
    explanation: Establishes ACTA1 as the second most common cause of NM.
  - reference: PMID:38500810
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;An expanded Next Generation Sequencing analysis targeting congenital myopathies genes revealed the presence of a novel heterozygous c.965 T &gt; A p. (Leu322Gln) variant in the ACTA1 gene, which encodes the skeletal muscle alpha-actin.&#34;
    explanation: Case report of a novel ACTA1 variant causing NM.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;ACTA1 encodes Î±-actin, one of the principal components of the contractile units in skeletal muscle.&#34;
    explanation: Describes ACTA1 function and confirms its role in severe NM with characteristic intranuclear rods and perinuclear space abnormalities.
  - reference: PMID:35810298
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;we measured an increased expression of cardiac Î±-actin in the muscle samples from the patients with longer lifespan, indicating a potential compensatory effect.&#34;
    explanation: Identifies compensatory cardiac alpha-actin expression as a potential modifier of ACTA1-NM severity.
- name: KBTBD13 Mutations
  association: Causative
  notes: &gt;
    Mutations in KBTBD13 cause nemaline myopathy type 6 (NEM6) with a distinctive
    slowness of movement phenotype and delayed muscle relaxation. NEM6 is the
    most prevalent form of nemaline myopathy in the Netherlands.
  evidence:
  - reference: PMID:39651462
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Nemaline myopathy type 6 (NEM6) is the most prevalent type of nemaline myopathy in the Netherlands.&#34;
    explanation: Establishes KBTBD13-NEM6 as a significant form of NM.
- name: KLHL40 Mutations
  association: Causative
  notes: &gt;
    Mutations in KLHL40, a CUL3 E3 ubiquitin ligase substrate-specific adapter,
    cause severe congenital nemaline myopathy through disruption of ubiquitin-
    mediated ER-Golgi trafficking and protein quality control.
  evidence:
  - reference: PMID:37432316
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Mutations in KLHL40, an E3 ubiquitin ligase cullin3 (CUL3) substrate-specific adapter protein, result in severe congenital nemaline myopathy&#34;
    explanation: Confirms KLHL40 mutations as causative for severe congenital NM.
- name: TPM3 Mutations
  association: Causative
  notes: &gt;
    Mutations in TPM3, encoding slow skeletal muscle alpha-tropomyosin, cause
    a form of nemaline myopathy with predominant type 1 fiber involvement.
- name: TPM2 Mutations
  association: Causative
  notes: &gt;
    Mutations in TPM2, encoding beta-tropomyosin, are a rarer cause of
    nemaline myopathy.
- name: TNNT1 Mutations
  association: Causative
  notes: &gt;
    Mutations in TNNT1, encoding slow skeletal muscle troponin T, cause a
    distinctive form found predominantly in the Old Order Amish population.
- name: CFL2 Mutations
  association: Causative
  notes: &gt;
    Mutations in CFL2, encoding cofilin-2, are a rare cause of nemaline myopathy
    with actin filament accumulation.
- name: LMOD3 Mutations
  association: Causative
  notes: &gt;
    Mutations in LMOD3, encoding leiomodin-3, cause severe congenital nemaline
    myopathy. Leiomodin-3 is involved in thin filament elongation.
- name: KLHL41 Mutations
  association: Causative
  notes: &gt;
    Mutations in KLHL41 cause nemaline myopathy. KLHL41 is involved in
    sarcomere maintenance and protein quality control.
treatments:
- name: Respiratory Support
  description: &gt;
    Nocturnal non-invasive ventilation (BiPAP) or continuous ventilatory support
    for respiratory muscle weakness. In NEB-NM, 55% of patients require ventilatory
    support with progressive need over time.
  treatment_term:
    preferred_term: noninvasive ventilation
    term:
      id: MAXO:0000506
      label: noninvasive ventilation
  evidence:
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;32% of patients with NM-NEB used a G tube, 35% were not able to walk without support, and 55% needed VS.&#34;
    explanation: Documents that the majority of NEB-NM patients require ventilatory support.
- name: Physical Therapy
  description: &gt;
    Ongoing physical therapy and rehabilitation to maintain mobility, prevent
    contractures, and optimize functional capacity.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Nutritional Support
  description: &gt;
    Gastrostomy tube feeding for patients with severe bulbar weakness and
    failure to thrive. In NEB-NM, 32% of patients require gastrostomy.
  treatment_term:
    preferred_term: gastrostomy
    term:
      id: MAXO:0001346
      label: gastrostomy
  evidence:
  - reference: PMID:36714460
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;32% of patients with NM-NEB used a G tube&#34;
    explanation: Quantifies the need for gastrostomy in NEB-NM patients.
- name: Orthopedic Management
  description: &gt;
    Management of scoliosis (bracing or surgical correction), foot deformities,
    and joint contractures.
  treatment_term:
    preferred_term: orthopedic procedure
    term:
      id: MAXO:0000477
      label: orthopedic procedure
- name: Genetic Counseling
  description: &gt;
    Genetic counseling for families to understand inheritance patterns, recurrence
    risk, and genetic testing options.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
- name: Fast Skeletal Muscle Troponin Activators (Investigational)
  description: &gt;
    Tirasemtiv and related fast skeletal muscle troponin activators increase
    submaximal muscle tension in preclinical NM models by enhancing thin filament
    calcium sensitivity. Improved respiratory efficiency observed in NEM3 mouse models.
  evidence:
  - reference: PMID:38376469
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo.&#34;
    explanation: Demonstrates tirasemtiv efficacy in a mouse model of ACTA1-related NM.
  - reference: PMID:38376469
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration.&#34;
    explanation: Shows improved respiratory efficiency with troponin activator treatment.
- name: Myosin Activators (Investigational)
  description: &gt;
    Omecamtiv mecarbil, a small-molecule cardiac myosin activator, substantially
    increased submaximal tension in type 1 muscle fibers from NEB-NM patients,
    with the largest effects in those with the lowest nebulin levels.
  evidence:
  - reference: PMID:38634969
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;OM treatment substantially increased submaximal tension across all NEM2 patients ranging from 87 to 318%, with the largest effects in patients with the lowest level of nebulin.&#34;
    explanation: Ex vivo human muscle fiber data showing omecamtiv mecarbil increases force production in NEB-NM.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Nemaline_Myopathy.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>